Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Ocrevus
Ocrevus is a medicine used to treat multiple sclerosis, helping reduce relapses and slow progression of disability.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ocrelizumab
Ocrelizumab is a substance used to treat multiple sclerosis by targeting specific immune cells to reduce inflammation and nerve damage.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire Amiens Picardie
Service neurologie
Amiens, France
Centre Hospitalier De La Cote Basque
Service neurologie
Bayonne, France
University Hospital Of Clermont-Ferrand
Service neurologie
Beaumont, France

Sponsor: F. Hoffmann-La Roche AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.